Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Ipamorelin is a pentapeptide (five amino acids) that selectively stimulates growth hormone release from the anterior pituitary by acting as a ghrelin receptor agonist — specifically, a growth hormone secretagogue receptor (GHS-R) agonist. Unlike older growth hormone-releasing peptides (GHRPs) such as GHRP-2 and GHRP-6, ipamorelin is noted in the research literature for its selectivity: it stimulates GH release with minimal concomitant elevation of cortisol, prolactin, or ACTH — hormones that earlier GHRPs tended to co-stimulate. This selectivity profile made ipamorelin an attractive research candidate in the early 2000s and contributed to its continued clinical research interest.
Preclinical and Early Clinical Research
The original characterization of ipamorelin by Novo Nordisk researchers established it as a potent and selective GH secretagogue. In rat studies, ipamorelin produced GH pulses comparable to GHRP-6 with significantly less cortisol elevation — a finding attributed to its receptor selectivity profile. The authors proposed ipamorelin as a research tool for studying GH secretion dynamics.
Separate from its GH-releasing properties, research has investigated ghrelin receptor agonism for gastrointestinal motility disorders. Early studies found ipamorelin and related peptides could accelerate gastric emptying and GI transit — a distinct research direction from the bodycomposition applications more commonly discussed.
Clinical Use Context
Ipamorelin is most commonly used in clinical practice in combination with a GHRH analogue such as CJC-1295 (modified GRF 1-29). The rationale is physiological: GH release is normally stimulated by two complementary hypothalamic hormones — GHRH (stimulatory) and ghrelin/GHRPs (amplifying). Combining a GHRH analogue with a GHRP can produce synergistic GH release while maintaining a more pulsatile pattern similar to natural physiology, compared to either agent alone.
Areas of Clinical Interest
- Age-related decline in GH and IGF-1 (somatopause)
- Body composition (lean mass support, adiposity)
- Sleep quality and recovery — GH is primarily secreted during slow-wave sleep
- Bone density monitoring in conjunction with GH pathway support
Safety and Prescribing Considerations
Ipamorelin is not FDA-approved and is available only as a compounded medication from licensed 503A pharmacies. Reported adverse effects in preclinical and early clinical literature include mild transient flushing, headache, and injection site reactions. As with all GH-pathway interventions, it is contraindicated in patients with active malignancy, and prescribers evaluate thyroid function, fasting glucose, and IGF-1 levels before initiating any secretagogue protocol.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
- Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9.
- Veldhuis JD, et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev. 2005;26(1):114-46.